<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336373</url>
  </required_header>
  <id_info>
    <org_study_id>H-35010 SCYTHE</org_study_id>
    <nct_id>NCT02336373</nct_id>
  </id_info>
  <brief_title>Treatment of Hemoglobin SC Disease With Hydroxyurea</brief_title>
  <acronym>SCYTHE</acronym>
  <official_title>SC Youth Treatment With Hydroxyurea Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell disease (SCD), specifically hemoglobin SC disease (HbSC), is a subtype of sickle&#xD;
      cell disease with typically higher hemoglobin and milder or later disease complications.&#xD;
      Sickle cell disease is a disorder in which red blood cells (RBCs) are abnormally shaped. This&#xD;
      can result in painful episodes, serious infections, and damage to body organs. One medication&#xD;
      used to treat sickle cell disease is hydroxyurea.&#xD;
&#xD;
      Hydroxyurea therapy offers significant benefits for infants, children, and adolescents with&#xD;
      sickle cell anemia. These include a reduction in the frequency of pain crises and acute chest&#xD;
      syndrome (inflammation of the lungs). Hydroxyurea has been given to many HbSC patients but&#xD;
      HbSC patients were not included in the large clinical trials used to test hydroxyurea in SCD,&#xD;
      so less is known about how HbSC patients respond to hydroxyurea.&#xD;
&#xD;
      The purpose of this research study is to see if hydroxyurea, a medication given to many&#xD;
      children with the most common type of sickle cell, those who are homozygous for the sickle&#xD;
      mutation (HbSS), helps children who have HbSC. The investigators will see if it helps by&#xD;
      giving a questionaire when the medication is started, and then every two months at a clinic&#xD;
      visit. The questionaire, called the Pediatric Quality of Life Inventory (PedsQL™) Sickle Cell&#xD;
      Disease Module version 3.0, measures quality of life. The investigators will also see how&#xD;
      hydroxyurea changes laboratory test numbers, and blood thickness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To be eligible to participate in this study, patients must have HbSC disease, have&#xD;
      experienced a sickle cell disease related complication, or have a score of 80 or lower on the&#xD;
      PedsQL™ Sickle Cell Disease Module version 3.0. This questionnaire will be offered to all&#xD;
      patients with HbSC seen in our clinic that consent to this study. If the patient is sexually&#xD;
      active, they will be offered birth control. If the patient chooses not to initiate effective&#xD;
      birth control, they will be tested at their scheduled vist with a urine pregnancy test. If&#xD;
      the patient becomes pregnant they will be removed from the study.&#xD;
&#xD;
      The maximum time patients will be on the study is 12 months after starting hydroxyurea&#xD;
      therapy, with an option to participate in a 2 year observation study following the end of the&#xD;
      study.&#xD;
&#xD;
      Patients will be assessed in the clinic every two months after starting treatment.&#xD;
      Hydroxyurea will be started at 10 mg/kg/day, and increased by 5 mg/kg/day at eight week&#xD;
      intervals if needed to reach a maximum tolerated dose (MTD). The most common side effect of&#xD;
      the drug is a drop in infection fighting cells, or white blood cells, so the medication will&#xD;
      be started at a low dose and the dose will be increased only if it is safe to do so.&#xD;
&#xD;
      Patients will be asked to allow the investigators to review information from their medical&#xD;
      records at the start of the study, and throughout the study. If the patient would like to&#xD;
      participate in the two year follow-up, their records will be reviewed during that period as&#xD;
      well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low enrollment&#xD;
  </why_stopped>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PedsQL SCDM</measure>
    <time_frame>6 months</time_frame>
    <description>Mean change in PedsQL™ Sickle Cell Disease Module version 3.0 score after achieving MTD compared with baseline.&#xD;
PedsQL™ Sickle Cell Disease Module version 3.0 scores are on a 100 point scale ranging from 0 to 100 with higher values indicating better quality of life.&#xD;
PedsQL: pediatric qulaity of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HVR at 45s-1</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in hematocrit to viscosity ratio (HVR) at 45s-1 at follow-up versus baseline. This is a measure of oxygen carrying capacity, as a higher hematocrit with lower viscosity indicates ability to deliver oxygen without slowed blood flow due to high viscosity or blood thickness. Higher values are associated with improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HVR at 225s-1</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in hematocrit viscosity ratio at 225s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DRBC</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in percent dense red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbF</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in fetal hemaglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MCV</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in mean corpuscular volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MCHC</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in mean corpuscular hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ARC</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in absolute reticulocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ANC</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in absolute neutrophil count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDH</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in lactate dehydrogenase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in UB Levels</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Change in unconjugated bilirubin levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hemoglobin SC Disease</condition>
  <arm_group>
    <arm_group_label>Hydroxurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
    <description>Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores</description>
    <arm_group_label>Hydroxurea</arm_group_label>
    <other_name>Hydrea</other_name>
    <other_name>Droxia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of HbSC disease&#xD;
&#xD;
          2. Score equal or lower than 80 on the PedsQL™ Sickle Cell Disease Module version 3.0&#xD;
&#xD;
          3. Have experienced a sickle cell disease related complication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure to meet inclusion criteria.&#xD;
&#xD;
          2. Hydroxyurea usage in the last 3 months.&#xD;
&#xD;
          3. Chronic RBC transfusion therapy.&#xD;
&#xD;
          4. Packed red blood cell transfusion in the last 3 months (temporary exclusion).&#xD;
&#xD;
          5. Pregnancy, or refusal to use medically effective birth control if female and sexually&#xD;
             active.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivien Sheehan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <results_first_submitted>March 5, 2020</results_first_submitted>
  <results_first_submitted_qc>September 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Vivien Sheehan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hemoglobin SC disease</keyword>
  <keyword>hydroxyurea</keyword>
  <keyword>quality of life</keyword>
  <keyword>viscosity</keyword>
  <keyword>red cell density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobin SC Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02336373/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydroxurea</title>
          <description>Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.&#xD;
hydroxyurea: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol closed early</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydroxyurea</title>
          <description>hydroxyurea (HU) at 10 mg/kg daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PedsQLTM 3.0 SCD Module score</title>
          <description>PedsQLTM 3.0 Sickle Cell Disease Module score</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in PedsQL SCDM</title>
        <description>Mean change in PedsQL™ Sickle Cell Disease Module version 3.0 score after achieving MTD compared with baseline.&#xD;
PedsQL™ Sickle Cell Disease Module version 3.0 scores are on a 100 point scale ranging from 0 to 100 with higher values indicating better quality of life.&#xD;
PedsQL: pediatric qulaity of life</description>
        <time_frame>6 months</time_frame>
        <population>Participants who achieved MTD of hydroxyureq per protocol with observed PEDSQL scores at 6-months and baseline (study entry).</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxurea</title>
            <description>Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.&#xD;
hydroxyurea: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PedsQL SCDM</title>
          <description>Mean change in PedsQL™ Sickle Cell Disease Module version 3.0 score after achieving MTD compared with baseline.&#xD;
PedsQL™ Sickle Cell Disease Module version 3.0 scores are on a 100 point scale ranging from 0 to 100 with higher values indicating better quality of life.&#xD;
PedsQL: pediatric qulaity of life</description>
          <population>Participants who achieved MTD of hydroxyureq per protocol with observed PEDSQL scores at 6-months and baseline (study entry).</population>
          <units>Score on PedsQL 3.0 SCD Module</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HVR at 45s-1</title>
        <description>Change in hematocrit to viscosity ratio (HVR) at 45s-1 at follow-up versus baseline. This is a measure of oxygen carrying capacity, as a higher hematocrit with lower viscosity indicates ability to deliver oxygen without slowed blood flow due to high viscosity or blood thickness. Higher values are associated with improvement.</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HVR at 45s-1</title>
          <description>Change in hematocrit to viscosity ratio (HVR) at 45s-1 at follow-up versus baseline. This is a measure of oxygen carrying capacity, as a higher hematocrit with lower viscosity indicates ability to deliver oxygen without slowed blood flow due to high viscosity or blood thickness. Higher values are associated with improvement.</description>
          <units>au</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HVR at 225s-1</title>
        <description>Change in hematocrit viscosity ratio at 225s</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HVR at 225s-1</title>
          <description>Change in hematocrit viscosity ratio at 225s</description>
          <units>au</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DRBC</title>
        <description>Change in percent dense red blood cells</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>hydroxyurea (HU) at 10 mg/kg daily</description>
          </group>
        </group_list>
        <measure>
          <title>DRBC</title>
          <description>Change in percent dense red blood cells</description>
          <units>percentage of dense red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbF</title>
        <description>Change in fetal hemaglobin</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbF</title>
          <description>Change in fetal hemaglobin</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MCV</title>
        <description>Change in mean corpuscular volume</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MCV</title>
          <description>Change in mean corpuscular volume</description>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MCHC</title>
        <description>Change in mean corpuscular hemoglobin concentration</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MCHC</title>
          <description>Change in mean corpuscular hemoglobin concentration</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hb</title>
        <description>Change in hemoglobin</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb</title>
          <description>Change in hemoglobin</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ARC</title>
        <description>Change in absolute reticulocyte count</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ARC</title>
          <description>Change in absolute reticulocyte count</description>
          <units>10^3 cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ANC</title>
        <description>Change in absolute neutrophil count</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ANC</title>
          <description>Change in absolute neutrophil count</description>
          <units>10^3 cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDH</title>
        <description>Change in lactate dehydrogenase</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDH</title>
          <description>Change in lactate dehydrogenase</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" spread="52.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in UB Levels</title>
        <description>Change in unconjugated bilirubin levels</description>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Inititiate hydroxyurea and reach MTD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in UB Levels</title>
          <description>Change in unconjugated bilirubin levels</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hydroxurea</title>
          <description>Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.&#xD;
hydroxyurea: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vivien Sheehan, MD, PhD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>(832) 824-4459</phone>
      <email>vxsheeha@txch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

